Shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) have earned an average recommendation of “Buy” from the ten ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $40.00.

Several research analysts have recently weighed in on RARX shares. Zacks Investment Research cut Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. BMO Capital Markets set a $33.00 target price on Ra Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, March 8th. Raymond James boosted their target price on Ra Pharmaceuticals from $39.00 to $44.00 and gave the stock a “strong-buy” rating in a report on Friday, March 8th. ValuEngine upgraded Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Finally, Stifel Nicolaus started coverage on Ra Pharmaceuticals in a report on Friday, February 8th. They set a “buy” rating and a $55.00 target price on the stock.

NASDAQ:RARX traded down $0.52 during trading hours on Friday, hitting $26.56. 517,700 shares of the stock were exchanged, compared to its average volume of 427,358. Ra Pharmaceuticals has a 52-week low of $4.78 and a 52-week high of $27.35. The firm has a market cap of $814.16 million, a P/E ratio of -12.89 and a beta of 0.83.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.47) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.02. The firm had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $2.50 million. Analysts anticipate that Ra Pharmaceuticals will post -2.16 earnings per share for the current year.

In other Ra Pharmaceuticals news, major shareholder Enterprise Associates 13 L. New bought 645,161 shares of the company’s stock in a transaction that occurred on Friday, December 14th. The shares were purchased at an average price of $15.50 per share, with a total value of $9,999,995.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Rajeev M. Shah acquired 1,006,452 shares of the company’s stock in a transaction on Friday, December 14th. The shares were purchased at an average cost of $15.50 per share, for a total transaction of $15,600,006.00. The disclosure for this purchase can be found here. 11.40% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of the business. Legal & General Group Plc grew its holdings in shares of Ra Pharmaceuticals by 57.7% during the fourth quarter. Legal & General Group Plc now owns 3,063 shares of the company’s stock worth $56,000 after purchasing an additional 1,121 shares during the last quarter. Meeder Asset Management Inc. grew its holdings in shares of Ra Pharmaceuticals by 62.8% during the fourth quarter. Meeder Asset Management Inc. now owns 5,311 shares of the company’s stock worth $96,000 after purchasing an additional 2,049 shares during the last quarter. Quantamental Technologies LLC purchased a new position in shares of Ra Pharmaceuticals during the fourth quarter worth about $44,000. Federated Investors Inc. PA purchased a new position in shares of Ra Pharmaceuticals during the third quarter worth about $65,000. Finally, Great West Life Assurance Co. Can purchased a new position in shares of Ra Pharmaceuticals during the fourth quarter worth about $63,000.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Further Reading: How is an ETF different from a mutual fund?

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.